EGFR and colorectal carcinoma: The success of monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling, as well as the advent of immune checkpoint inhibitors, has significantly improved therapeutic outcomes in CRC patients 39.